Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TOMPKINS FINANCIAL CORP Director's Dealing 2015

Nov 12, 2015

32217_dirs_2015-11-12_cae52d63-5810-4126-8a44-784e6c8c0c43.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TOMPKINS FINANCIAL CORP (TMP)
CIK: 0001005817
Period of Report: 2015-11-10

Reporting Person: HARTZ GREGORY J (EVP, Pres.&CEO Tompkins Trust)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-11-10 Common Stock M 892 $37.00 Acquired 16260.638 Direct
2015-11-10 Common Stock F 142 $54.31 Disposed 16118.638 Direct
2015-11-10 Common Stock D 576 $57.31 Disposed 15542.638 Direct
2015-11-10 Common Stock M 1870 $41.71 Acquired 17412.638 Direct
2015-11-10 Common Stock F 228 $57.31 Disposed 17184.638 Direct
2015-11-10 Common Stock D 1361 $57.31 Disposed 15823.638 Direct
2015-11-10 Common Stock M 519 $40.60 Acquired 16342.638 Direct
2015-11-10 Common Stock F 68 $57.31 Disposed 16274.638 Direct
2015-11-10 Common Stock D 368 $57.31 Disposed 15906.638 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-11-10 Stock Appreciation Rights (SAR) $37.00 M 892 Disposed 2021-08-19 Common Stock (892) Direct
2015-11-10 Stock Appreciation Rights (SAR) $41.7091 M 1870 Disposed 2019-09-17 Common Stock (1870) Direct
2015-11-10 Stock Appreciation Rights (SAR) $40.60 M 519 Disposed 2023-05-03 Common Stock (519) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3401.49 Indirect
Common Stock 2002.65 Indirect
Common Stock 55.278 Indirect

Footnotes

F1: Shares withheld for taxes.

F2: Deemed disposition of shares to satisfy the exercise price.

F3: Stock Appreciation Rights (SARs) were granted pursuant to the Tompkins Financial Corporation 2009 Equity Plan. SARs have a seven year vesting schedule with 0% vesting in year one, 17% vesting in years two through six, and 15% vesting in year seven. When exercised, the SARs will be settled in Common Stock of the Company. The grant will expire ten years from the date of the grant.